Votrient
An oral targeted therapy used to treat advanced kidney cancer and soft tissue sarcoma.
Where Pazopanib is approved
All regulators →Of the three regulators tracked here, the first to approve Pazopanib was the US, on 19 Oct 2009. It is approved in 3 of the 3 regulators tracked here.
- 1 EU orphan designation, most recently for treatment of renal-cell carcinoma (29 Jun 2006, withdrawn)
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
What health systems spend on Pazopanib
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Pazopanib works
All drug targets →- Macrophage colony stimulating factor receptor inhibitor InhibitorTarget: CSF1R colony stimulating factor 1 receptor✓ In ChEMBL and the Guide to Pharmacology
- Stem cell growth factor receptor inhibitor InhibitorTarget: KIT KIT proto-oncogene, receptor tyrosine kinase✓ In ChEMBL and the Guide to Pharmacology
- Tyrosine-protein kinase LCK inhibitor InhibitorTarget: LCK LCK proto-oncogene, Src family tyrosine kinaseChEMBL only
- Fibroblast growth factor receptor 3 inhibitor InhibitorTarget: FGFR3 fibroblast growth factor receptor 3ChEMBL only
- Fibroblast growth factor receptor 1 inhibitor InhibitorTarget: FGFR1 fibroblast growth factor receptor 1✓ In ChEMBL and the Guide to Pharmacology
- Platelet-derived growth factor receptor inhibitor InhibitorTarget: Platelet-derived growth factor receptor✓ In ChEMBL and the Guide to Pharmacology
- Vascular endothelial growth factor receptor inhibitor InhibitorTarget: Vascular endothelial growth factor receptor✓ In ChEMBL and the Guide to Pharmacology
- Tyrosine-protein kinase ITK/TSK inhibitor InhibitorTarget: ITK IL2 inducible T cell kinaseChEMBL only
- AngiosarcomaPhase 3
- Fallopian tube cancerPhase 3
- LeiomyosarcomaPhase 3
- LiposarcomaPhase 3
- Malignant epithelial tumor of ovaryPhase 3
- Ovarian carcinomaPhase 3
- Primary peritoneal carcinomaPhase 3
- SarcomaPhase 3
- Soft tissue sarcomaPhase 3
- Undifferentiated pleomorphic sarcomaPhase 3
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL477772, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3), ligand 5698, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
NICE appraisals of Pazopanib
All NICE appraisals →NICE, which decides whether the NHS in England should fund new medicines, has published 1 technology appraisal of Pazopanib. 1 is current, and 1 of it recommends it for at least some patients.
| Appraisal | NICE recommendation | Published | Status |
|---|---|---|---|
| Pazopanib for the first-line treatment of advanced renal cell carcinoma NICE TA215 | Recommended | 23 Feb 2011 Updated 1 Aug 2013 | Current |
NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
Patient leaflets for Pazopanib
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 10 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- EUEuropean Union: VotrientEMA product information: package leaflet and summary of product characteristics in every EU language.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Pazopanib
- ATC code
- L01XE11
- ChEMBL
- CHEMBL477772
- DrugBank
- DB06589
- PubChem CID
- 10113978
- CAS number
- 444731-52-6
- FDA UNII
- 7RN5DR86CK
- Wikidata
- Q7157043
- Wikipedia
- Pazopanib
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
What Votrient is used for
VOTRIENT is a kinase inhibitor indicated for the treatment of adults with: advanced renal cell carcinoma (RCC). ( 1.1 ) advanced soft tissue sarcoma (STS) who have received prior chemotherapy. ( 1.2 ) Limitations of Use : The efficacy of VOTRIENT for the treatment of patients with adipocytic soft tissue sarcoma or gastrointestinal stromal tumors has not been demonstrated. 1.1 Renal Cell Carcinoma VOTRIENT ® is indicated for the treatment of adults with advanced renal cell carcinoma (RCC). 1.2 Soft Tissue Sarcoma VOTRIENT is indicated for the treatment of adults with advanced soft tissue sarcoma (STS) who have received prior chemotherapy. Limitations of Use : The efficacy of VOTRIENT for the treatment of patients with adipocytic STS or gastrointestinal stromal tumors has not been demonstrated.
How it works
12.1 Mechanism of Action Pazopanib is a multi-tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR)-α and -β, fibroblast growth factor receptor (FGFR)-1 and -3, cytokine receptor (Kit), interleukin-2 receptor-inducible T-cell kinase (Itk), lymphocyte-specific protein tyrosine kinase (Lck), and transmembrane glycoprotein receptor tyrosine kinase (c-Fms). In vitro, pazopanib inhibited ligand-induced autophosphorylation of VEGFR-2, Kit, and PDGFR-β receptors. In vivo, pazopanib inhibited VEGF-induced VEGFR-2 phosphorylation in mouse lungs, angiogenesis in a mouse model, and the growth of some human …
Related clinical trials recruiting now
Explore more
How this page is built
The facts on this page are pulled directly from official U.S. FDA datasets — they are not written from memory. Each field below names the dataset it came from, so you can check it yourself.
- FDA Drug Label (openFDA) ↗ Indications, mechanism of action and pharmacologic class
- Drugs@FDA ↗ First FDA approval date and the company holding the application
- FDA Drug Shortage Database ↗ Current US supply / shortage status
Plain-English summaries and drug-class explainers are written and reviewed by Sreepriya Prasannan (MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany). Data is retrieved automatically from the sources above and cross-checked with AI-assisted verification (Anthropic's Claude) — brand and generic names are matched against the exact FDA product record so that a combination product or a different formulation cannot be mistaken for the drug on this page. An editor reviews the result before publication. We describe this in full in our editorial standards and corrections policy. The FDA data on this page was last retrieved on 6 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.